AlloVir to wind down PhIII trials for futility and will review strategic alternativesnews2023-12-26T14:55:21+00:00December 26th, 2023|Endpoints News|
AbbVie beat two rival bidders to acquire ImmunoGen for $10B, SEC filings shownews2023-12-26T14:46:41+00:00December 26th, 2023|Endpoints News|
Bristol Myers bets on neuroscience surge with $14B Karuna cash acquisitionnews2023-12-22T12:17:47+00:00December 22nd, 2023|Endpoints News|
FDA approves AstraZeneca, Ionis’ ATTR drug as showdown with Alnylam heats upnews2023-12-21T22:47:46+00:00December 21st, 2023|Endpoints News|
Calliditas wins full approval for steroid drug in rare autoimmune diseasenews2023-12-21T20:14:01+00:00December 21st, 2023|Endpoints News|
Pharma companies delist patents from FDA’s Orange Book following FTC challengesnews2023-12-21T19:40:16+00:00December 21st, 2023|Endpoints News|
FDA findings at Moderna’s Massachusetts facility don’t reflect quality, safety concerns, company saysnews2023-12-21T19:04:54+00:00December 21st, 2023|Endpoints News|
Servier found guilty of fraud in trial over pulled weight loss drug Mediator, reversing earlier rulingnews2023-12-21T17:35:55+00:00December 21st, 2023|Endpoints News|
Charles River to make Casgevy; Rentschler extends collab with ‘major client’; Andelyn works with Ultragenyxnews2023-12-21T17:08:40+00:00December 21st, 2023|Endpoints News|
Clene’s FDA update; JCR ends ties with Takeda, partners with AstraZeneca; Gilead ups stake in Hookipanews2023-12-21T16:12:56+00:00December 21st, 2023|Endpoints News|
